Research
IVIG
for Secondary Recurrent Miscarriage:
A Randomized Controlled Trial (RCT)
Study Doctor - Dr. C. Librach
We are conducting
an international trial to determine whether interavenous immunoglobulin
(IVIG), a drug used to treat many immune disorders, is effective in preventing
pregnancy loss. IVIG is thought to suppress adverse maternal immunological
responses to pregnancy in women with secondary recurrent miscarriage.
This study is being conducted through SWCH Fertility Centre and Create
Program Inc. Other include the Women's Health Centre in Vancouver, (Co-ordinating
Centre), University of Tennessee, University of Ottawa, Yale University
and the University of Chicago.
| Inclusion Criteria | |
| 1. | Women between 18 and 44 years of age. |
| 2. | History of a successful pregnancy followed by at least three miscarriages, all conceived with the same partner. |
| 3. | Genetic, hormonal, anatomical & autoimmune factors associated with recurrent miscarriage have been ruled out. |
This trial is supported by the Talecris Blood Partnership Fund, in association with the Canadian Blood Services. It is approved by Health Canada and the Food and Drug Administration (FDA).
For more information about this trial, please contact Rodica Mandel, Research Coordinator, at (416) 351-3800, X-2756 or Dr. C. Librach at (416) 813-4757.
 |
 |
